Skip to main content

Table 3 The pharmacokinetic profile of ADU-1805 after a single dose exposure in NHPs

From: Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint

DoseNCA half-lifeMid-range half-life
0.3 mg/kg0.88 days1.86 days
3 mg/kg1.89 days3.93 days
30 mg/kg2.95 days6.41 days